• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • image

    Developing precision therapies

    for type 1 diabetes

  • image

    Intralymphatic immunotherapy

    with Diamyd®

Company Presentation

 November 16, 2023

Our registrational trial DIAGNODE-3 and the industry partnership with JDRF , the leading patient organization for type 1 diabetes in the United States and leading funder of research in the field, constitute the heart of our development.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Annual Report 22/23


 Dates for financial information and other events
January 24, 2024
Quarterly Report I
Quarterly Report 1 2023/2024
March 27, 2024
Quarterly Report II
Quarterly Report 2 2023/2024
June 26, 2024
Quarterly Report III
Quarterly Report 3 2023/2024
October 9, 2024
Year-End Report
Year-End Report 2023/2024

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.
Read More


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research